Table 4.

Multivariate analysis of prognostic factors predictive of progression-free survival and overall survival in Korean RCC cases (primary multivariate model)^a)

Variable	Progression-free survival		Overall survival
	Hazard ratio	p-value	Hazard ratio	p-value
Age (≥ 60 yr vs. < 60 yr)	0.57	0.033	0.58	0.098
Gender (male vs. female)	0.83	0.534	1.01	0.972
Histology (non-clear vs. clear)	1.29	0.479	0.85	0.699
Prior nephrectomy (no vs. yes)	1.46	0.217	1.53	0.251
No. of metastatic sites (≥ 2 vs. ≤ 1)	1.79	0.134	2.81	0.037
Type of first VEGFr-TKI
(sorafenib vs. non-sorafenib)	0.76	0.473	1.86	0.162
Heng's criteriab)
(favorable vs. poor)	0.46	0.164	0.12	0.014
(intermediate vs. poor)	0.55	0.023	0.39	0.003

RCC, renal cell carcinoma; VEGFr-TKI, vascular endothelial growth factor-tyrosine kinase inhibitor.

^a)Primary multivariate model analysis was performed for evaluation of basic clinical factors, excluding previous VEGFr-TKI-related factors and development of everolimus-associated adverse event,

^b) Heng’s prognostic criteria: low Karnofsky performance scale (KPS) score < 80, low hemoglobin (< lower limit of normal), high corrected serum calcium concentration (> upper limit of normal), high platelet count (> upperlimit of normal), high neutrophil count (> upperlimit of normal), time from diagnosis to treatment < 1 year. Categories are defined as favorable=0, intermediate=1-2, or poor=3-6 risk factors.